Improve RBC quality and production Luspatercept BMS FDA approved for TD β-thalassemia and MDS-RS Cappellini et al., 2023 Mitapivat Agios FDA approved for PKD; in phase II clinical trial for NTD α- and ...

Candice Reeves is a financial writer based out of Nova Scotia. She specializes in personal finance, investing, and cryptocurrency. Her work is featured in leading publications across various ...

Dependency on future regulatory approvals for PYRUKYND and potential launches in thalassemia and sickle cell disease, which remain uncertain and could impact long-term revenue prospects.

TORONTO — RBC has quit the UN-backed Net-Zero Banking Alliance, leaving none of Canada's Big Six banks represented in the group. Canada's largest bank confirmed the move Friday, saying it has ...

Sickle cell disease (SCD) is an autosomal recessive blood disorder characterized by the presence of abnormal adult hemoglobin in red blood cells (RBCs ... of the cellular morphology, indicating ...

Iris Kulbatski, a neuroscientist by training and word surgeon by trade, is a science editor with The Scientist's Creative Services Team. She holds a PhD in Medical Science and a Certificate in ...

However, interferon is not associated with clinical improvement in CDA II, and there are no approved medications for achieving transfusion independence in CDA II. In beta thalassemia, ineffective ...

Patients with thalassemia major usually require regular blood transfusions to replenish healthy red blood cells to relieve the symptoms of anemia ... starting with a full blood count (FBC) and ...